EMA launches accelerated approval review of Valneva vaccine

0 0
Spread the love
Read Time:1 Minute, 3 Second

The European Medicines Agency (EMA) announced Thursday it is launching an accelerated review process for approval of the Covid 19 vaccine from Austrian-French biotechnology company Valneva. The EU already ordered up to 60 million Corona vaccine doses from Valneva several weeks ago. When a decision on the inactivated vaccine will be made is still open, he said.

Valneva’s inactivated vaccine contains killed components of the coronavirus for immunization. As such, it uses similar technology to traditional flu vaccines and is said to be able to be stored in normal refrigerators. In October, Valneva had announced “positive” initial results from its Phase 3 clinical trial of the vaccine. The drug was more effective than the AstraZeneca vaccine, it said. No inactivated Corona vaccine has yet been approved in the EU.

U.S. pharmaceutical company Novavax applied for approval of its Nuvaxovid vaccine in mid-November. This is a recombinant protein vaccine. The EMA promised an expedited review, so a decision is expected to be announced in “a few weeks.” The drug has about 90 percent efficacy, according to Novavax. The EU Commission also already has a purchase agreement with Novavax for up to 100 million doses of the vaccine.

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

This post has already been read 567 times!

Related posts

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Comment